Looking back on healthcare technology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including ...

Stifel’s latest review of Tandem Diabetes Care (TNDM) comes as the company navigates heightened competition and operational pressures. Recent product launches and regulatory clearances offer potential ...

Truist analyst Richard Newitter raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Hold rating on the shares as ...

Adults with insulin-treated type 2 diabetes benefit from automated insulin delivery systems regardless of their C-peptide ...

Fintel reports that on October 21, 2025, Stifel reiterated coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a Hold ...

Tandem Diabetes Care's iOS app and insulin pump has made more than 100 people need medical care, resulting in two hospitalizations this year so far. Tandem Diabetes recalled 85,863 devices in May and ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement ...

Spending more time in glucose range could help reduce adverse pregnancy outcomes, but available closed-loop insulin delivery systems are not customized to pregnancy-specific needs. In a randomized ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insights from a survey on Tandem Mobi ...

Tandem Diabetes Care, Inc. TNDM is well-poised for growth in the coming quarters, backed by its impressive lineup of new products. The flourishing diabetes market provides a favorable opportunity for ...

Tandem Diabetes Care (NASDAQ:TNDM) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement. Analysts estimate that ...

The accounting treatment for Tandem Choice had a high degree of complexity. The Tandem Choice program concluded in 2024, and there was no impact to sales for this program in 2025. Additional ...